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BACKGROUND
Human papillomavirus (HPV) causes a variety of
anogenital cancers and is considered the primary cause
of anal canal cancer 1,2. Anal cancer is a rare disease:
a total of 4650 diagnoses of anal carcinoma and 690
deaths were expected in the United States in 2007, with
approximately 40% of the diagnoses and deaths being
expected to occur in men. Other than cervical can-
cer, anal cancer was expected to be the most com-
monly diagnosed anogenital HPV-associated cancer
in 2007 3.
PARALLELS BETWEEN CERVICAL AND ANAL
CANCER
Although anal cancer is less common than cervical
cancer, its incidence in U.S. men is increasing, to 1.6
per 100,000 in 2005 from 0.6 per 100,000 in 1973. Dur-
ing the same period, the incidence of cervical cancer
in women decreased 4. An increasing incidence of anal
cancer noted also in Europe 5 is likely attributable to
increased anal disease occurring in immunocompro-
mised people and in men who have sex with men
(MSM) 6–8. Indeed, the risk ratio of observed to ex-
pected anal cancers has been reported to be 37.9 [95%
confidence interval (CI): 33.0 to 43.4] in men with HIV,
59.5 (95% CI: 51.5 to 68.4) in homosexual men with
HIV, and 5.9 (95% CI: 2.7 to 11.2) in heterosexual male
injection drug users with HIV 9. Appropriately, anal
cancer research to date has focused on these
populations. However, it is a concern that healthy het-
erosexual men constitute 90% of the male population
and that virtually no research regarding anal HPV has
targeted them. Epidemiologic research also indicates
that heterosexual men with HIV, even in the absence of
receptive anal intercourse, may have a high prevalence
of precancerous anal lesions associated with HPV 10.
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Finally, a clearer understanding of the risks associated
with anal HPV in heterosexual men may provide im-
portant contrasts that will help clarify the picture of
anal HPV-related morbidity and mortality in other
populations.
As in cervical cancer, most anal cancers are asso-
ciated with oncogenic HPV types 16 and 18 2,11. Given
an identical pathogen and similarity of the tissue (in-
cluding a transformation zone in the anal canal that is
bounded on each side by squamous and columnar epi-
thelium 12), HPV-induced carcinogenesis leading to
cervical cancer is comparable to the process that leads
to anal canal cancer. However, although the deploy-
ment of a preventive vaccine for HPV infection and
cervical dysplasia reflects important progress in pre-
venting cases of cervical cancer 13, policymakers do
not have the information needed to make informed
decisions about vaccine delivery to prevent anal can-
cer. The necessary information will hopefully come
from ongoing HPV vaccine studies in men and from
modelling efforts that can provide quantitative insight
into the economic and public health effects of the vac-
cine. However, accurate modeling of vaccine cost-
effectiveness with regard to anal HPV in men requires
more natural history data 14,15, and there are no such
studies, published or ongoing, of anal HPV in hetero-
sexual men. Indeed, few studies have estimated anal
HPV prevalence in heterosexual men.
PREVALENCE OF ANAL HPV
In a community-based study of anal HPV in 222 asymp-
tomatic heterosexual men, we recently estimated anal
HPV prevalence at 16.6% for the anal canal and 21.3%
for the perianal region. Of men with anal HPV, one
third harboured an oncogenic HPV type. Also, men with
anal HPV were more than twice as likely as men with
no anal HPV to be in their 20s [odds ratio (OR): 2.41;
95% CI: 1.05 to 5.55] 16. Two other smaller studies of
exclusively heterosexual men from a clinic for sexu-
ally transmitted infections and of partners of women
with confirmed HPV estimated anal HPV prevalences
of 1.2% 17 and 8% 18 respectively. The higher preva-
lence found in our sample may result from the use of
more sensitive test kits for HPV DNA detection.NYITRAY
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These prevalence data are a first step in under-
standing anal HPV in heterosexual men, but they need
to be confirmed in other populations of heterosexual
men. We are currently conducting a three-country anal
HPV prevalence study with men recruited by a collabo-
rative team led by Dr. Anna Giuliano of the H. Lee
Moffitt Cancer Center and Research Institute. Follow-
up longitudinal studies are needed, because these preva-
lence data can blend (and obscure) critical natural
history characteristics of anal HPV that are needed to
inform prevention strategies.
SUMMARY
Little is known about anal HPV in men—and especially
in heterosexual men. Against this backdrop of scarce
data, the incidence of anal cancer has risen consider-
ably. Although knowledge about anal HPV in MSM has
advanced in the last decade (important advances, given
the increased rate of anal cancer in MSM), the much
greater number of heterosexual men and the lack of
epidemiologic data describing anal HPV in heterosexual
men should prompt additional research in this area.
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